"A METHOD FOR THE PREPARATION OF THIAZOLOPYRIMIDINES'

A method for the preparation of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof; from a compound of the formula: (IV); wherein L represents a leaving group.

Full Text

METHODS
The present invention relates to methods for preparing thiazolopyrimidine compounds, intermediate compounds used in such methods, thiazolopyrimidme compounds so prepared and their use in therapy.
In our published PCT patent application WO-01/25242 we describe pharmaceutically active compounds of the general formula I
NR2R3
(Figure Remove)
and pharmaceutically acceptable salts and solvates thereof, and methods for their preparation. Such methods include treatment of a compound of formula
L
(Figure Remove)
where L is a leaving group such as chlorine, with an amine HNR2R3.
We have now devised an advantageous process for preparing compounds of the formula I. This novel process involves protection of the thiazole nitrogen atom and gives an improved yield of final product when compared with the prior art method described in WO-01/25242. By way of example for a compound of the above formula we have achieved displacement of a chlorine leaving group by a group NR2R3 and subsequent conversion of the 2-amino group to a carbonyl group, with about 40% overall yield. In contrast we have achieved about 70% overall yield for the same product starting from a compound of formula IV as set out hereinafter and wherein the leaving group L is chlorine.
Therefore in a first aspect of the invention we provide a method for the preparation of a compound of formula (I) or a pharmaceutically acceptable salt or sob/ate thereof:
NR2R3
(Figure Remove)
in which
R1 represents a Ca-C? carbocyclic, Ci-C8 alkyl, Ca-Ce alkenyl or C2-Cg alkynyl group, each of the groups being optionally substituted by one or more substituent groups independently selected from halogen atoms, -OR4, -NR5R6, -CONR5R6, -COOR7, -NR8COR9, -SR10, -SOaR10, -SOzNRV, -NR8SO2R9 or an aryl or heteroaryl group, both of which may be optionally substituted by one or more substituents independently selected from halogen atoms, cyano, nitro, -OR4, -NR5R6, -CONRV, -COOR7, -NR8COR9, -SR10, -6, -NR8SOaR9, Ci-Cg alkyl or trifluoromethyl groups;
R2 and R3 each independently represent a hydrogen atom, or a C3-C7 carbocyclic,
Ci-Cg alkyl, Ca-Q alkenyl or Ca-Ce alkynyl group, the latter four groups may be optionally
substituted by one or more substituent groups independently selected from;
(a) halogen atoms, -OR4, -NRV, -CONR^6, -COOR7, -NR8COR9, -SR10, -SOzR10,
-SO2NR5R6, -NR8SO2R9;
(b) a 3-8 membered ring optionally containing one or more atoms selected from O, S, NR8
and itself optionally substituted by Ci-Ca-alkyl or halogen; or
(c) an aryl group or heteroaryl group each of which may be optionally substituted by one
or more substituents independently selected from halogen atoms, cyano, nitro, -OR4, -NR^R6,
-CONR5R6, -NR8COR9, -SOaNR^6, -NR8SO2R9, Ci-Q alkyl and trifluoromethyl groups;
R4 represents hydrogen, Ci-Cg alkyl or a phenyl group the latter two of which may be
optionally substituted by one or more substituent groups independently selected from halogen
atoms, phenyl, -OR11 and -NR12R13.
R5 and R6 independently represent a hydrogen atom or a d-Q alkyl or phenyl group the latter two of which may be optionally substituted by one or more substituent groups independently selected from halogen atoms, phenyl, -OR14 and -NR15R16, -CONR15R16, -NR15COR16, -SONR15R16,
or
R5 and R6 together with the nitrogen atom to which they are attached form a 4- to
7-membered saturated heterocych'c ring system optionally containing a further heteroatom
selected from oxygen and nitrogen atoms, which ring system may be optionally substituted by
one or more substituent groups independently selected from phenyl, -OR14, -COOR14, -
NR15R16, -CONR15R16, -NR15COR16, -SONR15R16, NR^SOaR16 or CrC6 aDcyl, itself
optionally substituted by one or more substituents independently selected from halogen atoms
and -NR15R16 and -OR17 groups;
R10 represents a hydrogen atom or a Ci-Ce-alkyl or a phenyl group, the latter two of which
may be optionally substituted by one or more substituent groups independently selected from
halogen atoms, phenyl, -OR17 and -NR15R16; and
each of R7, R8, R9, R11, R12, R13, R14 R15, R16, R17 independently represents a hydrogen atom
or a Ci-Q alkyl, or a phenyl group;
which method comprises contacting
wherein L is a leaving group
with a thiazole nitrogen protecting group reagent under appropriate reaction conditions to
form a compound of the formula
wherein PG is a protecting group,
reacting the compound of formula ni with an amine of formula HNR2R3
to form a compound of formula
NR2R3
(Figure Remove)

and deprotection of the compound of formula n to give a compound of the formula I, and simultaneous or sequential conversion to a pharmaceutically acceptable salt or solvate thereof.
Convenient leaving groups will be apparent to the chemist of ordinary skill, such as disclosed in 'Advanced Organic Chemistry', 4* edition, J. March, Wiley-Interscience (1992). Such groups will include halogen atoms such as chlorine or bromine. Chlorine is a preferred leaving group for use in the invention.
Additional protection may be provided for the amine of formula HNR2^3 for example where R2 and/or R3 comprises a hydroxy or amino group. By way of non-limiting example we refer to Example 3(d) where a particular diol is introduced and protected via the compound (2,2,5-trimethyl-l,3-dioxan-5-yl)amine.
Convenient protecting groups will be apparent to the chemist of ordinary skill It wOl be appreciated that the more stable the resulting product upon protection the likelihood of increased difficulty in removing the protecting group afterwards. Additionally, some resulting products upon protection may not be sufficiently stable to isolation by standard laboratory methods. The protection and deprotection of functional groups is fuUy described in 'Protective Groups in Organic Synthesis', 2nd edition, T. W. Greene & P. G. M. Wuts, Wiley-Interscience (1991).
Examples of suitable protecting groups for the given transformations, to provide compounds of formula I, involving removal under appropriate hydrolytic conditions are [with suitable protecting group agents indicated in square brackets] methoxymethyl [chloromethyl methyl ether], and particularly ethoxymethyl [chloromethyl ethyl ether or diethoxymethane], benzyloxymethyl [benzyl chloromethyl ether], pivatoyloxymethyl [chloromethyl pivalate],
2-(trimethylsilyl)ethoxymethyl [2-(trimethylsilyl)ethoxymethyl chloride], l-(ethoxy)ethyl [ethyl vinyl ether] and 2-tetrahydropyranyl [3,4-dihydro-(2H)-pyran]. Each individual protecting group listed above and its use represents a particular independent aspect of the invention. Base-assisted removal of the 2-(phenylsulfonyl)ethyl [phenyl vinyl sulfone] protecting group under non-aqueous conditions is a suitable method for achieving these transformations.
The approach is also suited to catalytic reduction methods for removal of appropriate protecting groups. Such protecting groups include benzyl, diphenylmethyl, triphenyhnethyl and benzyloxymethyl. Allyl as a protecting group can be removed under metal-assisted conditions and 4-methoxybenzyl, 2,4-dimethoxybenzyl and di(4-methoxyphenyl)methyl can be removed under oxidative conditions. Acyl, benzoyl, pyrrolidinyknethyl and urea-type protecting groups are other examples that can be removed under appropriate hydrolytic conditions. Representative chloroformate reagents do not yield a carbamate protecting group, for example a benzylchtoroformate reagent is found to yield a benzyl protecting group.
In the context of the present specification, unless otherwise indicated, an aDcyl or alkenyl group or an aJkyl or alkenyl moiety in a substituent group may be linear or branched. Aryl groups include phenyl and naphthyL Heteroaryl groups include 5- or 6-membered aromatic rings containing one or more heteroatoms selected from N, S, and O. Examples include pyridine, pyrimidine, thiazofe, oxazole, pyrazok, imidazole, furan.
Certain compounds of formula (I) are capable of existing in stereoisomeric forms. It will be understood that the methods of the invention may be used with all geometric and optical isomers of the compounds of formula (I) and mixtures thereof including racemates. The scientist of ordinary skill will be able to select appropriate intermediate compounds to introduce the appropriate stereochemistry for -NR2R3 and R1 (if appropriate).
Particular compounds of formula (I) are those in which R1 represents an optionally substituted benzyl group. More particularly R1 represents benzyl or benzyl substituted by one or more Ci-Cs aDcyl, d-Q alkoxy or halogen atoms.
When R2 and R3 represent a group substituted by one or more 3-8 membered rings optionally containing one or more atoms selected from O, S or NR8, examples of such groups include piperidine, pyrrolidine, piperazine and morpholine.
Conveniently one of R2 or R3 is hydrogen and the other is Ci-Cg alkyl substituted by hydroxy and one or more methyl or ethyl groups. More conveniently one of R2 or R3 is hydrogen and the other is CH(CH3)CH2OH) CH(Et)CH2OH, CCCHa^CHaOH or

CH(CH2OH)2. When one of R2 or R3 is hydrogen and the other is CH(CH3)CH2OH or CH(Et)CH2OH the resulting compounds of formula (I) are particularly in the form of the (R) isomer.
Particular compounds of the formula I for use in the method of the invention include those wherein R1 represents a (2,3-difluorophenyl)methyl group and R2 and R3 together represent a Ci-g alkyl group optionally substituted by one or more substituent groups independently selected from -OR4 wherein R4 represents hydrogen or a Ci-g alkyl group.
Further particular compounds of the formula I include compounds of the formula la
(Figure Remove)
wherein each Rx is independently selected from hydrogen, a CM alkyl group optionally substituted by hydroxy, annno, -OC^ alkyl, -S-CM alkyl, -N-CW alkyl, -NHSO2R, or -CONRa and provided that both Rx are not hydrogen or amino.
More particular compounds of the invention are wherein each Rx is independently
iy
selected from hydrogen and hydroxymethyl, provided that both R are not hydrogen.
The invention also provides novel salts of the above compounds namely the potassium salt of the compound wherein one Rx is hydrogen and the other is hydroxymethyl (cf. Example 2) and both the sodium and potassium salts of the compound wherein both Rx are hydroxymethyl (Examples 3 and 4).
Compounds of the formula n are novel and represent a further aspect of the invention.
Preparation of a compound of the formula I via deprotection of a compound of the formula n is novel and represents a further aspect of the invention.
Compounds of the formula HI are novel and represent a further aspect of the invention.
Preparation of a compound of the formula n via reaction of a compound of the formula IE with an amine of formula HNRaRa is novel and represents a further aspect of the invention.
Compounds of the formula IV are novel (except for 7-chloro-5-[[(2,3-dffluorophenyl)memyl]lM)]tMazolo[4,5-d]pyiiinidin-2-(3fl)-one) and represent a further aspect of the invention. They are conveniently prepared hy reaction of a compound of formula
(Figure Remove)

with a reagent providing a leaving group L.
Such reaction represents a farther independent aspect of this invention.
Compounds of the formula V are novel and represent a further aspect of the invention. They are conveniently prepared by reaction of a compound of formula
(Figure Remove)
VI
with a halocarbonylsulfenylhalide. Convenient halogen atoms are independently selected from chlorine and bromine, chlorine is a preferred halogen atom and chlorocarbonylsulfenylchloride is a preferred reagent.
Such reaction represents a further independent aspect of this invention.
Compounds of formula VI are novel and represent a further, independent aspect of the invention, they are conveniently prepared by reaction of a compound of formula

with a compound of formula L- R1, wherein L is a leaving group and R1 is as hereinbefore defined.
Such reaction is known for reaction of the compound of formula VII with a compound L- R1 wherein L is bromine and R1 is (2,3-difluorophenyl)met;hyl, this is disclosed in our WO-03/24966.
The compound of formula VII is conveniently provided as the monohydrate (cf. Example 1 (a)) and is commercially available, for example from Aldrich, Acros or Lancaster.
In a further aspect of the invention we provide the preparation of a compound of formula I from a compound of Formula V, via compounds of Formula W, in, n, using methods as set out hereinbefore.
In a further aspect of the invention we provide the preparation of a compound of formula I from a compound of Formula VI, via compounds of Formula V, IV, EQ, n, using methods as set out hereinbefore.
In a further aspect of the invention we provide the preparation of a compound of formula I from a compound of Formula VU, via compounds of Formula VI, V, IV, ffl, n, using methods as set out hereinbefore.
The invention will now be illustrated but not limited by the following Fjtamples:
methvlethvllaniinolthiazok>r4-one
(a) 6-amino-2-[t(2,3-difluorophenyI)inethyl]thio]-4-pyrimidinol

To a stirred suspension of 7-amino-5-[[(2,3-
difhiorophenyl)methyl]t]ifo][l,3]oxato (5.03g) and
benzyltrimethylaintnonivan chloride (2.58g) in acetonitrile (25ml) at 50 °C, was first added AT.JV-diethylanilme (2.46g) followed by acetonitrile (5ml), and then phosphorus oxychloride (7.41g) followed by acetonitrile (5ml). The reaction mixture was heated to reflux and maintained at this temperature for 36 hours, before cooling to ambient temperature and adding to water (25ml) at 50 °C with stirring over 30 minutes. An additional acetonitrile (5ml) rinse of the reaction vessel was added to the drown-out mixture, before heating to 75 °C. and sbwly cooling to 25 °C at
1H NMR: 8 (DMSO-d6) 7.45 (1H, t), 7.38 (1H, m), 7.22 (1H, m), 4.50 (2H, s), 3.43 (1H, br.s).
(d) 5-[[(2,3-dlifluort)phenyl)methyl]tm
(Figure Remove)

(i) To a stirred suspension of 7-cWoro-5-[[(2,3-difluorophenyl)metty^
p-toluenesulfonic acid (29.4mg) in toluene (40ml) at 60 °C was added 3,4-dihydro-2.H-pyrau (1.83g) over 1 hour. The reaction mixture was held at 60 °C for 2 hours and then cooled at 0.5 °C/min to ambient temperature. Saturated aqueous sodium bicarbonate solution (20ml) was first added to the reaction mixture, before stirring for 1 hour. The settled phases were separated and the organic solution further treated with saturated brine (20ml). The brine phase was removed and toluene (2ml) added to the remaining organic phase to give a clear orange solution of 7-cUoro-5-[[(23-dMuorophenyl)memyl]tMo]-3-(tetrahydro-2jff-pyran-2-yl)thiazolo[4,5-d]pyrimidin-2-(3fl)-one. (44.5ml).
(ii) To a portion of the clear orange solution (10ml) was added tetrahydrofuran (5ml), sodium carbonate (0.70g) and (D)-alaninol (0. 49g). The stirred reaction mixture was heated to 60 °C for 1.5 hours and then further heated to 65 °C for 24 hours. Water (10ml) was added to the reaction mixture at 60 °C and stirring continued for 1 hour. The settled aqueous phase was removed and cyclohexane (15ml) added to the stirred reaction mixture over 1 hour at 60 °C, during which time the product crystallised. The resulting mixture was stirred at 60 °C for a further 2 hours, cooled to ambient temperature at 0.25 "C/tnin and then cooled to 0-5 °C The crystallised product was isolated, washed twice with toluene (3ml), to afford the title compound as an off-white solid (1.15g).
1H NMR: 8 (DMSO-d6) 7.50 (IH, br.s), 7.41 (IH, t), 7.33 (IH, m), 7.15 (IH, m), 5.54 (IH, d), 4.76 (IH, br.s), 4.44 (2H, s), 4.22 (IH, br.m), 4.00 (IH, d), 3.56 (IH, m), 3.43 (IH, m), 3.34 (IH, m), 2.71 (IH, m), 1.90 (IH, br.d), 1.62 (2H, br.d), 1.48 (2H, br.m), 1.10 (3H, d).
(e) 5-t[(23-difluoroPhenyl)methyl]thio]-7-[[(l«)-2-hydroxy-l-methylethyl]amino]thiazolo[4,5-^]pyrimidin-2-(3H)-one
To a stirred solution of 5-[[(2,3-difluorophenyl)methyl]thio]-7-[[(l/?)-2-hydroxy- 1-me%le%l]aininQ]-3-(tetrahydro-2#-pyran^
(lO.Og) in acetonitrile (200ml), water (36ml) and tetrahydrofuran (30ml) at 65 °C was added 1M hydrochloric acid (23.25ml) over 3 hours. The product crystallised during the addition time. The mixture was cooled to 25 °C and the product collected by filtration, washing firstly with water (30ml) then acetonitrile (30ml), to afford the title compound as an off-white solid (7.79g).
*H NMR: 8 (DMSO-d6) 12.41 (1H, br.s), 7.35 (3H, m), 7.15 (1H, m), 4.73 (1H, m), 4.40 (2H, m), 4.21 (1H, br.m), 3.44 (1H, m), 3.37 (1H, m), 1.09 (3H, d).
To a stirred suspension of 7-chtoro-5-[[(23-difluorophenyl)rnethyl]thio]thiazolo[4,5-d]pyrimidin-2-(3#)-one (31.62g), as prepared in Example 1 (c) above, in butyronitrile (150ml) at room temperature was added diisopropylethylamine (16ml, l.Oeq), forming a solution. A butyronitrile line wash was applied (10ml). Phenylvinylsulfone (20g, 1.3eq) was dissolved in butyronitrile (80ml) in a separate flask and this solution was added to the vessel, followed by a line wash with butyronitrile (70ml). The orange solution was heated to an internal temperature of 100°C. After 18 hours HPLC showed almost complete consumption of the starting material (3.36% 7-chforo-5-[[(23-difluorophenyl)methyl]thio]thiazolo[4,5-rf]pyrimidin-2-(3flr)-one remained)*. At this point further diisopropylethylamine (16ml,
l.Oeq) was added to the mixture at 50°C, followed by a small line wash of butyronitrile (5ml). D-alaninol (9.25mLs, 1.3eq) was added, followed by a line wash of butyronitrile (5ml). After 6.5 hrs HPLC showed almost complete conversion of the reaction intermediate (2.52% 7-chloro-5-[[(23-dffluorophenyl)methyl]tMo]-3-[2-(jphenylsulfonyl)ethyl]thiazolo[4,5-d]pyrimidin-2-(3fl)-one remained). The reaction was allowed to cool from 100 to 50°C over 6.5hrs and held at 50°C under nitrogen for 64 hrs. In order to get a homogeneous sample the reaction was re-heated to 100°C (1.19% 7-chloro-5-[[(2,3-difluorophenyl)methyl]thio]-3-[2-(phenylsulfonyl)e
(phenylsulfonyl)ethyl3tMazoto[4,5-^pyrimidin-2-(3J:iO-one was obtained with 88% yield
(44.33g, HPLC area = 98.75%).
*H NMR: 8 (DMSO-d6) 1.09 (d, 3H), 1.25 (m, IH), 3.37 (dquin, 2H), 3.80 (t, 2H), 4.13 (t, 2H), 4.20 (m, IH), 4.39 (s, 2H), 4.75 (t, IH), 7.15 (m, IH), 7.33 (m, 2H), 7.46 (d, IH), 7.55 (t, 2H), 7.66 (t, IH), 7.82 (d, 2H).
(b) Isolation of intermediate 7-chloro-5-[[(2,3-difluorophenyl)methyl]thio]-3-[2-(pheny!sulfonyl)ethyl]thiazolo[4,5-
This may be achieved by following the process as outlined in (a) above but adding water to mixture at 50°C (at point *). The mixture is then cooled to room temperature producing a precipitate which is isolated by filtration.
*H NMR: 8 (DMSO-d6) 3.86 (t, 2H), 4.21(1, 2H), 4.49 (s, 2H), 7.20 (m, IH), 7.37 (m, 2H), 7.55 (t, 2H), 7.65 (t, IH), 7.83 (d, 2H).
(c) Preparation of 5-[[(2,3-difluorophenyl)methyl]thio]-7-[[(lR).2-hydroxy-l-methylethyl]amino]thiazolo[4,5-rf]pyrimidin-2(3H)-one, potassium salt

K(Figure Remove)
.5ml) at room temperature under
nitrogen, was added potassium/-butoxide (0.449, l.OSeq), The resulting suspension was
heated to an internal temperature of 75-78°C (reflux). After 1.5 hours at this temperature,
water (4.5ml) was added and the reaction became a solution. The reaction was reheated to
75-78°C before sampling for HPLC analysis. The sample showed almost complete
consumption of the starting material (0.36% 5-[[(2,3-difliK)rophenyl)memy5thio]-7-[[(lJR)-2-
hydroxy- l-methytethyl] amim]-3-[2-(phenylsulfonyl)emyl]miazo^
one remained). The reaction was allowed to cool, seeded at 50°C with 5-[[(2,3-
difluorophenyl)memyl]thio]-7-[[(l£)-2-hyd^ thiazolo[4,5-
d]pyrhiudin-2-(3H)-one, potassium salt (2mgs) and then cooled to room temperature. The precipitate was 'aged' at room temperature for 1 hour before filtering. The cake was washed with propan-2-ol (3 x 4ml). The white solid was collected and dried in a vacuum oven over night at 50°C. This process yielded 63% (0.96g) of a white solid which was of high purity (99.65% by HPLC area).
1H NMR: 8 (DMSO-d6) 1.06 (d, 3H), 3.26-3.43 (m, 2H), 4.09 (quin, 1H), 4.34 (m, 2H), 4.65 (bs, 1H), 5.59 (d, 1H), 7.12 (q, 1H), 7.28 (q, 1H),7.37 (t, 1H).
Alternatively, the compound of Example l(e) may be reacted with potassium hydroxide to give the title compound.
Evarnplp 3
sodium
(a) trimethyl-l,3-dioxan-5-yl)aniiuo]thia2olo[4,5-rf]pyrimidin-2(3H)-one

(Figure Remove)

To a stirred suspension of 7-chtoro-5-[[(23-^iifluorophenyl)meihyl3t;hio]thiazoto[4,5-
d\pyrJtaadm.'2-(3H)-oj», prepared as shown in Example 1, steps (a) to (c), (l.Og, l.Oeq) in
butyronitrile (15ml) at room temperature under nitrogen, was added diisopropylethylamine
(0.5ml, l.Oeq), forming a solution. Phenylvinylsulfone (0.63g, l,3eq) was added to the
vessel The orange solution was heated to an internal temperature of 100°C. After 18 hours
HPLC showed almost complete consumption of the starting material (0.93% 7-chloro-5-
[[(23-difluorophenyl)inethyl]thk)]tiuazob[4,5-
point further diisopropylethylamine (0.5ml, l.Oeq) was added to the mixture at 50°C, followed by (2,2,5-trmiemyl-13^k>xan-5-yl)arnme (0.63g, l.Seq). (2,2,5-trimethyl-l,3-dioxan-5-yl)amine is disctosed in J. Nat. Prod, 1999,62, 963-968.
After over night stir at 100°C HPLC showed incomplete consumption of the reaction intermediate (32.56% 7-cWoro-5-[[(23-4ifluorophmyl)rnemyl]thio]-3-[2-(pnenylsulfonyl)emyl]mia2»lo[4,5-rflpyrimidin-2-(3flr)-one remained). A further portion of (2,2,5-trinKmyl-13-dioxmi-5-yl)amhie (0.21g, O.Seq) was added. The reaction took another 4 days at 100°C by which time the HPLC showed ro-5-[[(23-dMuorophenyl)inernyl]thw3-3-[2-(pr^
(3#)-one, as well as 13.42% of 5-[[(2,3-difluorophenyl)methyl]thio]-7-[[2-hydroxy-l-faydroxyn»thyl)4-ri«rnylethyl]an
2(3H)-one where the acetonkie had cleaved in situ). The reaction was alto wed to cool from 100 to 50°C. Whilst at 50°C water (10ml) was added. No precipitate was observed. The
layers were separated, organic layer washed further with water (10ml), dried over MgSO4, filtered and evaporated to dryness to give an orange oil.
Purification was achieved by chromatography over silica eluting with 20 - 30% ethyl acetate / ihexane on silica to yield a white solid.
'H NMR: 8 (DMSO-d6) 1.27 (s, 3H), 1.33 (s,3H), 1.36 (s, 3H), 3.67 (d, 2H), 3.82 (t, 2H), 4.14 (m, 4H), 4.38 (s, 2H), 7.20 (m, 2H), 7.34 (t, 2H), 7.54 (t, 2H), 7.66 (t, 1H), 7.81 (d, 2H).
(b) 5-[[(2^-(lifliiQroplienyl)me&^^ methylethyl]ainrao]-3-[2-(paenylsulfonyl)e^^
(Figure Remove)

We claim:
1. A method for the preparation of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof:
(Formula Removed)
in which
R1 represents a C3-C7 carbocyclic, C1-C8 alkyl, C2-C6 alkenyl or C2-C6 alkynyl group, each of the groups being optionally substituted by one or more substituent groups independently selected from halogen atoms, -OR4, -NR5R6, -CONR5R6, -COOR7, -NR8COR9, -SR10, -SO2R10 ,-SO2NR5R6,-NR8SO2R9 or an aryl or heteroaryl group, both of which may be optionally substituted by one or more substituents independently selected from halogen atoms, cyano, nitro, -OR4, -NR5R6, -CONR5R6, -COOR7, -NR8COR9, -SR10, -SO2R10, -SO2NR5R6, -NR8SO2R9, C1-C6 alkyl or trifluoromethyl groups;
R2 and R3 each independently represent a hydrogen atom, or a C3-C7 carbocyclic, C1-C8 alkyl, C2-C6 alkenyl or C2-C6 alkynyl group, the latter four groups may be optionally substituted by one or more substituent groups independently selected from:
(a) halogen atoms, -OR4, -NR5R6, -CONR5R6, -COOR7, -NR8COR9, -SR10, -SO2R10, -SO2NR5R6, -NR8SO2R9;
(b) a 3-8 membered ring optionally containing one or more atoms selected from O, S,
NR8 and itself optionally substituted by C1-C3-alkyl or halogen; or
(c) an aryl group or heteroaryl group each of which may be optionally substituted by
one or more substituents independently selected from halogen atoms, cyano, nitro,-
OR4,-NR5R6, -CONR5R6, -NR8COR9, -SO2NR5R6, -NR8SO2R9, C1-C6 alkyl and
trifluoromethyl groups;
R4 represents hydrogen, C1-C6 alkyl or a phenyl group the latter two of which may be optionally substituted by one or more substituent groups independently selected from halogen atoms, phenyl,-OR11 and-NR12R13
R5 and R6 independently represent a hydrogen atom or a C1-C6 alkyl or phenyl group the latter two of which may be optionally substituted by one or more substituent groups independently selected from halogen atoms, phenyl, -OR14 and -NR15R16, -CONR15R16, -NRl5COR16, - SONR15R16, NR15SO2R16 or
R5 and R together with the nitrogen atom to which they are attached form a 4-to 7-membered saturated heterocyclic ring system optionally containing a further heteroatom selected from oxygen and nitrogen atoms, which ring system may be optionally substituted by one or more substituent groups independently selected from phenyl,-OR14,-COOR14, -NR15R16, -CONR15R16, -NR15COR16, -SONR15R16, NR15SO2R16 or C1-C6 alkyl, itself optionally substituted by one or more substituents independently selected from halogen atoms and-NRl5R16 and-OR17 groups; R10 represents a hydrogen atom or a C1-C6-alkyl or a phenyl group, the latter two of which may be optionally substituted by one or more substituent groups independently selected from halogen atoms, phenyl,-OR17 and -NR15R16 ; and each of R7, R8, R9, R11, R12, R13 R14 R15, R16, R17 independently represents a hydrogen atom or a C1-C6 alkyl, or a phenyl group,
which method comprises contacting
(Formula Removed)
wherein L is a leaving group
with a thiazole nitrogen protecting group reagent under appropriate reaction
conditions to form a compound of the formula
(Formula Removed)
wherein PG is a protecting group,
reacting the compound of formula III with an amine of formula HNR R to form a
compound of formula
(Formula Removed)
and deprotection of the compound of formula II to give a compound of the formula I, and simultaneous or sequential conversion to a pharmaceutically acceptable salt or solvate thereof.
2. A method as claimed in claim 1 and wherein R1 represents an optionally substituted benzyl group.
3. A method as claimed in claim 1 or claim 2 and wherein one of R2 or R3 is hydrogen and the other is C1-C8 alkyl substituted by hydroxy and one or more methyl or ethyl groups.
4. A compound selected from
5-[[(2,3-difluorophenyl)methyl]thio-7-[[(1R)-2-hydroxy-l-methylethyl] amino] thiazolo [4,5pyrimidin-2 (3H) -one, potassium salt;
5-[[(2,3-difluorophenyl) methyl] thio]-7-[[2-hydroxy-l-(hydroxymethyl)-l-methylethyl] amino] thiazolo [4, 5-d] pyrimidin-2 (3H) -one, sodium salt; and 5- [ [ (2, 3-difluorophenyl) methyl] thio]-7-[[2-hydroxy-l-(hydroxymethyl)-l-methylethyl] amino] thiazolo [4, 5-d] pyrimidin-2 (3H) -one, potassium salt.
5. A compound and a method for the preparation of a compound substantially as herein described with reference to foregoing examples.